Home Cart Sign in  
Chemical Structure| 346688-38-8 Chemical Structure| 346688-38-8

Structure of Pridopidine
CAS No.: 346688-38-8

Chemical Structure| 346688-38-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pridopidine exhibits high affinity towards sigma 1 receptor (S1R) (Ki = 70-80 nM) which can counteract the effects of excessive or insufficient dopaminergic transmission and it can used as a dopamine (DA) stabilizer.

Synonyms: ACR16; ASP2314; ACR16 compound

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pridopidine

CAS No. :346688-38-8
Formula : C15H23NO2S
M.W : 281.41
SMILES Code : CCCN1CCC(C2=CC=CC(S(=O)(C)=O)=C2)CC1
Synonyms :
ACR16; ASP2314; ACR16 compound
MDL No. :MFCD09835586
InChI Key :YGKUEOZJFIXDGI-UHFFFAOYSA-N
Pubchem ID :9795739

Safety of Pridopidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Pridopidine

GPCR

Isoform Comparison

Biological Activity

Target
  • D2 receptor

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00665223 Huntington's Disease Phase 3 Completed - Austria ... More >> LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz Graz, Styria, Austria, 8036 Innsbruck Medical University, Anichstraße 35 Innsbruck, Tyrol, Austria, A-6020 Belgium University Hospital Gasthuisberg Leuven, Flemish Brabant, Belgium, 3000 France Hôpital Purpan, Place Docteur-Baylac, Bâtiment F Toulouse Cedex 9, Midi-Pyrénées region, France, 31059 CHU Roger Salengro Lille Cedex, Nord-Pas de Calais, France, 59037 Hôpital Nord, CHU d'Amiens, Service de Neurologie Amiens Cedex 1, Picardie, France, 80054 CHU La Timone, 264 Rue Saint Pierre Marseille Cedex 05, Provence-Alpes-Cote d'Azur, France, 13385 Germany Universitätsklinik Ulm, Neurologie/ Oberer Eselberg 45/1 Ulm, Baden-Württemberg, Germany, 89081 Klinikum rechts der Isar der Technischen Universität München, Neurologische Klinik und Poliklinik, Ismaninger Str. 22 München, Bavaria, Germany, 81675 Isar Amper Klinikum gemeinnützige GmbH, Klinik Taufkirchen (Vils), Bräuhausstr.5 Taufkirchen (Vils), Bavaria, Germany, 84416 St. Josef Hospital, Ruhr University Bochum, Gudrunstraße 56 Bochum, North Rhine-Westphalia, Germany, 44791 Westfaelische Wilhelms-Universitaet Muenster, Klinik fur Neurologie Muenster, North Rhine-Westphalia, Germany, 48149 Universitat Dresden, Klinikum Carl Gustav Carus, Fetscherstr. 74 Dresden, Saxony, Germany, 01307 Klinik für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Schumannstrasse 20/21 Berlin, Germany, 10117 Italy Fondazione IRCCS Istituto Nazionale Neurologico "Carlos Besta", Department of Movement Disorders, 11 via Celoria Milano, Lombardy, Italy, 20133 IRCCS Neuromed, Localita Camarelle Pozzilli, Molise, Italy, 86077 Portugal University Hospital of Coimbra, Av. Rissaya Barreto Coimbra, Baixo Mondego, Portugal, 3000-075 Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz Lisboa, Portugal, 1649-028 Spain Hospital Mútua de Terrassa, C/ Castell Terrassa, Catalonia, Spain, 08225 Hospital Clinic of Barcelona, Calle Villarroel, 170 Barcelona, Spain, 08036 Hospital Ramon y Cajal, Carretera Colemenar km 9.100 Madrid, Spain, 28034 Hospital Universitario La Fe, Avda. Campanar 21, Valencia, Spain, 46009 United Kingdom R&D Headquarters, Barberry Centre, 25 Vincent Drive Birmingham, England/West Midlands, United Kingdom, B15 2SG Department of Clinical Genetics, St Mary's Hospital, Hathersage Road Manchester, North West England, United Kingdom, M13 9WL First Floor Argyll House, Fosterhill, Cornhill Road Aberdeen, Scotland, United Kingdom, AB25 2ZR SE Scotland Genetic Service, Western General Hospital, Crewe Road Edinburgh, Scotland, United Kingdom, EH4 2XU Churchill Hospital, Old Road, Headington Oxford, South East England, United Kingdom, OX3 7LJ Academic Neurology Unit, E Floor Medical School Beech Hill Road Sheffield, South Yorkshire, United Kingdom, S10 2RX Institute of Human Genetics, Centre for Life, Central Parkway Newcastle on Tyne, Tyne and Wear, United Kingdom, NE1 3BZ Cardiff University School of Medicine, Department of Neurology & Medical Genetics, Heath Park Cardiff, Wales, United Kingdom, CF14 4XN Cambridge Centre for Brain repair, Cambridge University Cambridge, United Kingdom, CB2 2PY Less <<
NCT02006472 Huntington's Disease Phase 2 Completed - -
NCT01306929 Huntington Disease Phase 2 Completed - United States, Indiana ... More >> Teva Investigational Site 045 Indianapolis, Indiana, United States, 46202 United States, Iowa Teva Investigational Site 024 Iowa City, Iowa, United States, 52242 United States, Maryland Teva Investigational Site 028 Baltimore, Maryland, United States, 21287 United States, New York Teva Investigational Site 037 Albany, New York, United States, 12208 Teva Investigational Site 001 Rochester, New York, United States, 14620 United States, Ohio Teva Investigational Site 089 Cincinnati, Ohio, United States, 45267 United States, Pennsylvania Teva Investigational Site 018 Philadelphia, Pennsylvania, United States, 19107 United States, Washington Teva Investigational Site 220 Kirkland, Washington, United States, 98034 Canada, British Columbia Teva Investigational Site 048 Vancouver, British Columbia, Canada, V6T 2B5 Canada, Ontario Teva Investigational Site 231 Ottawa, Ontario, Canada, K1G 4G3 Canada Teva Investigational Site 118 London, Canada, N6A 5A5 Teva Investigational Site 039 Toronto, Canada, M3B 2S7 Less <<
NCT00724048 Huntington Disease Phase 2 Phase 3 Completed - -
NCT02494778 Huntington's Disease PHASE2 TERMINATED 2018-01-12 Teva Investigational Site 1220... More >>4, Los Angeles, California, 90095, United States|Teva Investigational Site 12201, Englewood, Colorado, 80113, United States|Teva Investigational Site 12196, Washington, District of Columbia, 20007, United States|Teva Investigational Site 12206, Baltimore, Maryland, 21287, United States|Teva Investigational Site 12200, Manhasset, New York, 11030, United States|Teva Investigational Site 12203, New York, New York, 10032, United States|Teva Investigational Site 12198, Rochester, New York, 14618, United States|Teva Investigational Site 12211, Winston-Salem, North Carolina, 27157, United States|Teva Investigational Site 12209, Pittsburgh, Pennsylvania, 15213, United States|Teva Investigational Site 12208, Salt Lake City, Utah, 84108, United States|Teva Investigational Site 12210, Richmond, Virginia, 23230, United States|Teva Investigational Site 78055, Caulfield South, 3162, Australia|Teva Investigational Site 78058, West Perth, 6005, Australia|Teva Investigational Site 78057, Westmead, 2145, Australia|Teva Investigational Site 33021, Innsbruck, A-6020, Austria|Teva Investigational Site 33027, Wien, 1010, Austria|Teva Investigational Site 11036, Toronto, Ontario, M3B 2S7, Canada|Teva Investigational Site 35123, Angers cedex 9, 49933, France|Teva Investigational Site 35122, Creteil, 94010, France|Teva Investigational Site 35125, Lille Cedex, 59037, France|Teva Investigational Site 35124, Marseille Cedex 5, 13385, France|Teva Investigational Site 35121, Salouel, 80054, France|Teva Investigational Site 35165, Toulouse, 31059, France|Teva Investigational Site 32408, Berlin, 10117, Germany|Teva Investigational Site 32410, Bochum, 44791, Germany|Teva Investigational Site 32409, Munster, 48149, Germany|Teva Investigational Site 32407, Ulm, 89081, Germany|Teva Investigational Site 30083, Firenze, 50134, Italy|Teva Investigational Site 30080, Milano, 20133, Italy|Teva Investigational Site 30082, Napoli, 80131, Italy|Teva Investigational Site 30081, San Giovanni Rotondo, 71013, Italy|Teva Investigational Site 38059, Leiden, 2333 ZA, Netherlands|Teva Investigational Site 53150, Gdansk, 80-462, Poland|Teva Investigational Site 53149, Krakow, 31-505, Poland|Teva Investigational Site 53148, Poznan, 60-529, Poland|Teva Investigational Site 53151, Warsaw, 02-957, Poland|Teva Investigational Site 50215, Kazan, 420101, Russian Federation|Teva Investigational Site 50213, Moscow, 125367, Russian Federation|Teva Investigational Site 50214, Nyznij Novgorod, 603126, Russian Federation|Teva Investigational Site 34058, Birmingham, B15 2SG, United Kingdom|Teva Investigational Site 34054, Cambridge, CB2 2PY, United Kingdom|Teva Investigational Site 34059, Cardiff, CF14 4XN, United Kingdom|Teva Investigational Site 34055, Manchester, M13 9WL, United Kingdom|Teva Investigational Site 34061, Newcastle-Upon-Tyne, NE6 4QD, United Kingdom|Teva Investigational Site 34056, Oxford, OX3 9DU, United Kingdom|Teva Investigational Site 34057, Sheffield, S10 2JF, United Kingdom Less <<
NCT03019289 Health Volunteers, Huntington ... More >>Disease Less << Phase 1 Completed - Germany ... More >> Teva Investigational Site 32648 Leipzig, Germany, 04103 Less <<
NCT06069934 Amyotrophic Lateral Sclerosis NO_LONGER_AVAILABLE - University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35233, United States|Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|University of California, San Diego Health, La Jolla, California, 92037-0886, United States|UC Irvine, Orange, California, 92868, United States|California Pacific Medical Center - Forbes Norris MDA/ALS Research Center, San Francisco, California, 94109, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States|Hospital for Special Care, New Britain, Connecticut, 06053, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Nova Southeastern University, Fort Lauderdale, Florida, 33314, United States|University of South Florida, Tampa, Florida, 33612, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, 83704, United States|Northwestern University, Chicago, Illinois, 60611, United States|The University of Chicago, Chicago, Illinois, 60637, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|The University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Lahey Hospital Medical Center, Burlington, Massachusetts, 08105, United States|University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01655, United States|Essentia Health, Duluth, Minnesota, 55805, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Washington University, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Stony Brook University Hospital, Stony Brook, New York, 11794, United States|SUNY Upstate, Syracuse, New York, 13210, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27514, United States|Duke University, Durham, North Carolina, 27705, United States|OhioHealth, Columbus, Ohio, 43214, United States|Providence ALS Clinic, Portland, Oregon, 97213, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, 19140, United States|Austinl Neuromuscular Center, Austin, Texas, 78759, United States|Texas Neurology, Dallas, Texas, 75206, United States|UT Southwestern Medical Center, Dallas, Texas, 75390, United States|Nerve and Muscle Center of Texas, Houston, Texas, 77030, United States|Virginia Commonwealth University, Richmond, Virginia, 23298, United States|(CAMC) Charleston Area Medical Center, Charleston, West Virginia, 25304, United States|UW Health University Hospital, Madison, Wisconsin, 53792, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|CHALS-CCT Program, UPR-MSC, San Juan, 00935, Puerto Rico Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.55mL

0.71mL

0.36mL

17.77mL

3.55mL

1.78mL

35.54mL

7.11mL

3.55mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories